<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>342</serviceExecutionTime><Drug id="22514"><DrugName>E coli EPVaccine, Axis Genetics</DrugName><DrugSynonyms><Name><Value>E coli EPVaccine, Axis Genetics</Value></Name><Name><Value>E coli Edible Plant Vaccine, Axis Genetics</Value></Name></DrugSynonyms><CompanyOriginator id="22759">Axis Genetics plc</CompanyOriginator><CompaniesSecondary><Company id="22759">Axis Genetics plc</Company><Company id="24137">Boyce Thompson Institute for Plant Research Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="22759" type="Company"><TargetEntity id="4296593273" type="organizationId">Axis Genetics PLC</TargetEntity></SourceEntity><SourceEntity id="24137" type="Company"><TargetEntity id="5035523850" type="organizationId">Boyce Thompson Institute for Plant Research Inc</TargetEntity></SourceEntity><SourceEntity id="120" type="ciIndication"><TargetEntity id="D004927" type="MeSH"></TargetEntity><TargetEntity id="-1969770508" type="omicsDisease"></TargetEntity><TargetEntity id="803" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C1">Phase 1 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="120">Escherichia coli infection</Indication></IndicationsSecondary><ActionsSecondary><Action id="12371">Subunit vaccine</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology></Technologies><LastModificationDate>2017-08-31T08:25:34.000Z</LastModificationDate><ChangeDateLast>2006-02-06T12:27:54.000Z</ChangeDateLast><AddedDate>1999-03-11T09:48:32.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="22759" linkType="Company"&gt;Axis Genetics&lt;/ulink&gt; was developing an edible plant vaccine (EPV) targeting Escherichia coli heat-labile enterotoxin (ETEC) to protect against traveller's diarrhea [&lt;ulink linkID="317720" linkType="reference"&gt;317720&lt;/ulink&gt;]. The company was conducting research in order to produce a vaccine co-expressing more than one antigenic determinant against E coli in plants. It is presumed that development was discontinued due to Axis being placed in admin following a failed private placement in late 1999 [&lt;ulink linkID="341955" linkType="reference"&gt;341955&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A phase I trial with the transgenic orally-active vaccine was conducted by the Boyce Thompson Institute in 1997, using the vaccine in its original form, ie expressing a single antigen against the B subunit of  ETEC (LT-B). Volunteers ingested 50 to 100 g of raw transgenic potato tuber (about 0.75 mg per dose) in this trial, the results of which showed that the vaccine was safe and induced both systemic and mucosal immune responses in healthy volunteers [&lt;ulink linkID="285531" linkType="reference"&gt;285531&lt;/ulink&gt;], [&lt;ulink linkID="320141" linkType="reference"&gt;320141&lt;/ulink&gt;], [&lt;ulink linkID="331786" linkType="reference"&gt;331786&lt;/ulink&gt;]. Further phase I trials of the improved version were expected in 2001 [&lt;ulink linkID="317776" linkType="reference"&gt;317776&lt;/ulink&gt;], [&lt;ulink linkID="318291" linkType="reference"&gt;318291&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Preclinical studies in which a crude soluble tobacco leaf extract was administered to mice by gavage and compared with a purified E coli expressed LT-B administered in the same way demonstrated that the plant-derived material elicited both serum and mucosal antibodies and thus retained the immunogenic properties of the E coli-derived LT-B. Later studies demonstrated that mice fed with 20 to 50 microg LT-B per dose of transformed transgenic potato tubers developed anti-LT-B IgG and IgA titres equivalent to, or greater than, antibody titres elicited in mice given 5 microg of purified E coli LT-B by gavage and were protected against subsequent challenge with LT [&lt;ulink linkID="320141" linkType="reference"&gt;320141&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="24137">Boyce Thompson Institute for Plant Research Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="120">Escherichia coli infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-11-01T00:00:00.000Z</StatusDate><Source id="341955" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22759">Axis Genetics plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="120">Escherichia coli infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-11-01T00:00:00.000Z</StatusDate><Source id="341955" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="22759">Axis Genetics plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="120">Escherichia coli infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-03-11T09:48:33.000Z</StatusDate><Source id="317720" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24137">Boyce Thompson Institute for Plant Research Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="120">Escherichia coli infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-03-11T00:00:00.000Z</StatusDate><Source id="317776" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput>